(NASDAQ: NKTX) Nkarta's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.93%.
Nkarta's earnings in 2025 is -$109,239,000.On average, 9 Wall Street analysts forecast NKTX's earnings for 2025 to be -$99,008,170, with the lowest NKTX earnings forecast at -$103,013,952, and the highest NKTX earnings forecast at -$97,694,216. On average, 8 Wall Street analysts forecast NKTX's earnings for 2026 to be -$96,934,254, with the lowest NKTX earnings forecast at -$113,454,555, and the highest NKTX earnings forecast at -$70,846,951.
In 2027, NKTX is forecast to generate -$115,912,004 in earnings, with the lowest earnings forecast at -$139,208,044 and the highest earnings forecast at -$81,287,554.